Get the Stockscreener App
3.08
3.36%
0.10
After Hours:
3.08
Eledon Pharmaceuticals Inc stock is traded at $3.08, with a volume of 198.13K.
It is up +3.36% in the last 24 hours and up +7.32% over the past month.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
See More
Previous Close:
$2.98
Open:
$3
24h Volume:
198.13K
Relative Volume:
0.91
Market Cap:
$179.65M
Revenue:
-
Net Income/Loss:
$-40.33M
P/E Ratio:
-1.7207
EPS:
-1.79
Net Cash Flow:
$-39.53M
1W Performance:
+2.67%
1M Performance:
+7.32%
6M Performance:
-33.04%
1Y Performance:
+13.24%
1-Day Range:
$3.00
$3.175
1-Week Range:
$2.91
$3.265
52-Week Range:
$2.30
$5.54
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Name
Eledon Pharmaceuticals Inc
Sector
Industry
Phone
949-238-8090
Address
19800 MACARTHUR BLVD., IRVINE
Compare ELDN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
3.08 | 179.65M | 0 | -40.33M | -39.53M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Guggenheim | Buy |
| May-13-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-23-21 | Initiated | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Stock (ELDN) Latest News
Short Interest in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Declines By 12.3% - Defense World
Northern Trust Corp Boosts Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
Jane Street Group LLC Makes New $504,000 Investment in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
What Makes Eledon Pharmaceuticals (ELDN) a New Buy Stock - MSN
Eledon Pharmaceuticals Reports Q1 2025 Progress and Financials - TipRanks
What is Noble Financial’s Estimate for ELDN Q2 Earnings? - Defense World
Cubist Systematic Strategies LLC Takes $101,000 Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
Balyasny Asset Management L.P. Invests $134,000 in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
FY2025 EPS Estimates for ELDN Boosted by Cantor Fitzgerald - Defense World
Q2 EPS Estimate for Eledon Pharmaceuticals Lifted by Analyst - Defense World
Dimensional Fund Advisors LP Sells 11,190 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
Cantor Fitzgerald maintains Overweight on Eledon Pharmaceuticals stock By Investing.com - Investing.com UK
Tower Research Capital LLC TRC Purchases 6,412 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
Eledon (ELDN) Advances Tegoprubart for Organ Transplant Therapy - GuruFocus
Eledon (ELDN) Advances Tegoprubart for Organ Transplant Therapy | ELDN Stock News - GuruFocus
Eledon Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results - The Manila Times
Barclays PLC Makes New $288,000 Investment in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
Eledon Pharmaceuticals (ELDN) Expected to Announce Quarterly Earnings on Thursday - Defense World
Undercovered Dozen: Gevo, Eledon, Dorian, Iridium + - Seeking Alpha
Eledon Pharmaceuticals Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView
Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX) and Baxter International (BAX) - The Globe and Mail
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) has caught the attention of institutional investors who hold a sizeable 46% stake - Yahoo Finance
Geode Capital Management LLC Buys 285,043 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Eledon Pharmaceuticals appoints Deloitte as new auditor By Investing.com - Investing.com Nigeria
Midday Stock Roundup: Evolus, ICU Medical down - Orange County Business Journal
Eledon Pharmaceuticals appoints Deloitte as new auditor - Investing.com
Charles Schwab Investment Management Inc. Purchases 15,000 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
Virtu Financial LLC Takes $82,000 Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
Is Eledon Pharmaceuticals (ELDN) The Hot Biotech Stock Under $5? - Insider Monkey
Equities Analysts Set Expectations for ELDN FY2025 Earnings - Defense World
Research Analysts Set Expectations for ELDN FY2025 Earnings - Defense World
What is Leerink Partnrs’ Forecast for ELDN Q1 Earnings? - Defense World
Eledon Pharmaceuticals Reports 2024 Financial Results and Clinical Advances - MSN
We're Hopeful That Eledon Pharmaceuticals (NASDAQ:ELDN) Will Use Its Cash Wisely - Yahoo
10 Hot Biotech Stocks Under $5 - Insider Monkey
Eledon Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Eledon Pharmaceuticals Inc. (ELDN) reports earnings - Quartz
Eledon Pharmaceuticals FY Operating Expenses USD 70.577 Million -March 20, 2025 at 04:48 pm EDT - Marketscreener.com
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results - The Manila Times
Eledon Achieves Historic Transplant Milestones as Cash Position Hits $140M - StockTitan
Eledon Pharmaceuticals (ELDN) to Release Earnings on Thursday - Defense World
Institutional investors in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) see US$25m decrease in market cap last week, although long-term gains have benefitted them. - Simply Wall St
Eledon Pharmaceuticals Inc Stock (ELDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):